-
1.THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF NOS3 审中-公开
标题翻译: 遗传风险的心力衰竭评价:影响NOS3遗传变异的公开(公告)号:EP1865770A4
公开(公告)日:2010-12-29
申请号:EP06749580
申请日:2006-04-07
申请人: NITROMED INC , UNIV PITTSBURGH
CPC分类号: A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
-
2.THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF BETA 1 ADRENERGIC RECEPTOR GLY389ARG POLYMORPHISM 审中-公开
标题翻译: 遗传风险评估心力衰竭:遗传变异对GLY389ARG-多态性BETA 1肾上腺素能受体的影响公开(公告)号:EP1945030A4
公开(公告)日:2009-10-21
申请号:EP06816322
申请日:2006-10-04
申请人: NITROMED INC , UNIV PITTSBURGH
CPC分类号: C12Q1/6883 , A61K31/34 , A61K31/502 , A61K45/06 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
-
3.ASSESSMENT OF HEART FAILURE RISK USING GENETIC ASSESSMENT OF G-PROTEIN BETA-3 SUBUNIT POLYMORPHISM 审中-公开
标题翻译: 遗传风险因心力衰竭评估:EFFECT多态性的G蛋白β-3亚基的遗传变异的公开(公告)号:EP2010169A4
公开(公告)日:2010-09-08
申请号:EP07754872
申请日:2007-04-04
申请人: NITROMED INC , UNIV PITTSBURGH
IPC分类号: A01N43/58 , A01N33/02 , A01N33/18 , A01N33/24 , A01N43/08 , A01N43/60 , A01N45/00 , A61K31/04 , A61K31/135 , A61K31/34 , A61K31/495 , A61K31/50 , A61K31/56
CPC分类号: A61K31/21 , A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
-
4.THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM 审中-公开
标题翻译: 遗传风险评估心力衰竭:影响醛固酮合成酶基因多态性的遗传变异的公开(公告)号:EP1943361A4
公开(公告)日:2009-04-15
申请号:EP06825494
申请日:2006-10-04
申请人: NITROMED INC , UNIV PITTSBURGH
IPC分类号: C12Q1/68
CPC分类号: C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
-
5.
公开(公告)号:EP2661630A4
公开(公告)日:2014-04-30
申请号:EP11847336
申请日:2011-12-05
申请人: UNIV PITTSBURGH , PREVENCIO INC
发明人: LA FRAMBOISE WILLIAM A , MASTERSON ROBERT V , MARROQUIN OSCAR C , MCNAMARA DENNIS M , MULUKUTLA SURESH R , LOMAKIN ALEKSEY
CPC分类号: G06F19/3431 , G01N33/6893 , G01N2570/00 , G01N2800/324 , G01N2800/50 , G01N2800/60 , G16H50/30
摘要: The present invention relates to biomarker signatures and associated methods for identifying patients that are not likely to manifest significant coronary artery disease. It is based, at least in part, on a study performed on serum samples of 239 patients with clinical symptoms of cardiac distress, some of whom required invasive intervention (stent placement or bypass graft surgery). A set of biomarkers was identified as exhibiting different levels of expression in subjects that did, or did not, require invasive intervention. Further, an algorithm was developed which, using serum levels of these biomarkers, assigned a score to a given patient that was indicative of whether that patient required invasive intervention.
摘要翻译: 本发明涉及用于鉴定不太可能表现出明显的冠状动脉疾病的患者的生物标志物标志和相关方法。 至少部分基于对239例心脏窘迫临床症状患者的血清样本进行的研究,其中一些患者需要侵入性干预(支架置入或旁路移植手术)。 鉴定了一组生物标志物,表明在进行或不需要侵入性干预的受试者中具有不同程度的表达。 此外,开发了一种算法,使用这些生物标志物的血清水平,给予给定患者一个评分,指示该患者是否需要侵入性干预。
-
-
-
-